Polycythemia Vera

Printable Tools & Resources

Download and/or print helpful patient education tools and resources to support your journey with Jakafi® (ruxolitinib).

Graphic of Understanding Polycythemia Vera guide

Understanding Polycythemia Vera: A guide for patients and caregivers

This guide was written to help people with polycythemia vera and their loved ones better understand the disease and its treatment. It also provides information to help you prepare to talk with your Healthcare Professional about whether treatment with Jakafi may be right for you.

Download the Guide
Graphic of Getting Started With Jakafi document

Getting Started With Jakafi

This guide was created to help support patients who are starting their journey with Jakafi. Get important information about how Jakafi works, plus detailed instructions for taking Jakafi, including what to expect during treatment and important safety information.

Download the Guide
Graphic of Polycythemia Vera, Spleen Size & You document

Polycythemia Vera, Spleen Size & You

This informative guide explains the various functions of the spleen and highlights why spleen size is an important health focus for people with polycythemia vera (PV). It also discusses how patients can take a more active role in partnering with their Healthcare Professionals to help identify and monitor the signs and symptoms of spleen enlargement in PV.

Download the Guide Email the Guide
Graphic of PV Appointment Workbook document

PV Healthcare Appointment Workbook

This interactive workbook provides 10 practical tips to help you prepare for your upcoming PV healthcare visits. You can use this comprehensive resource to help make the most of both in-office and/or telehealth visits with your Healthcare Professionals.

Download the Workbook Email the Workbook

Connect With
a Patient
Like Cam

Connect With a
Patient Like Cam

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering

Expand Collapse



Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.